搜索：Biotech
-
Newco/出海的机会来了！欧美药企、VC公司紧急寻找VAV1分子胶、STAT6降解剂、可透脑分子胶产品
2025年以来，分子胶领域捷报频传，重磅进展不断，展现出强劲的发展势头。 达歌生物完成超2000万美元的A+轮融资，资金将用于推进其新型分子胶降解剂的临床开发，涵盖核心管线——靶向…
-
Approaching $6 Billion! XtalPi Secures Major Out-Licensing Agreement
On August 5, 2025, XtalPi Inc. entered into a collaboration agreement with Dovetree (a com…
-
Has the mRNA Vaccine Era Collapsed? Kennedy Announces Cancellation of Funding for 22 mRNA Vaccine Projects
On August 5, 2025, Robert F. Kennedy Jr., the newly appointed U.S. Secretary of Health and…
-
mRNA疫苗天塌了？肯尼迪宣布将取消22个mRNA疫苗项目的拨款
Newco/出海的机会来了！欧美VC公司紧急寻找口服环肽产品。请立即联系药时代BD团队（BD@drugtimes.cn）！ 全文共1666字，共1图 预计阅读时间：6分钟 当地时间…
-
打不过上一代？如何冲击千亿美元市场
全文共2000字，共1图 预计阅读时间：5分钟 在非阿片类镇痛药的研发中，Vertex遭遇了新的挫折。其Nav1.8钠通道抑制剂VX-993在一项2期临床试验中未能在疼痛缓解方面优…
-
CellOrigin’s DLL3 CAR-T Accepted by CDE, China Leads Global DLL3 Therapeutic Development
August 2, 2025 – The clinical trial application for SNC115, a DLL3-targeting chimeric anti…
-
World’s First Clinical Improvement! Sun Yat-sen Memorial Hospital Collaborates with Shize Bio to Advance Universal iPSC-Derived Neural Cell Therapy for Spinal Cord Injury
On July 17, 2025, a landmark achievement was made in the “world’s first”…
-
Everest Medicines has strategically increased its stake in I-Mab, becoming its largest shareholder
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
-
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
For more DrugTimes bio-news, please follow DrugTimes. Many thanks!
-
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
For more bio-news, please follow DrugTimes. Many thanks!
